MEDX ... anybody following? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MEDX ... anybody following?

MEDX 31.58

+1.4%

Nov 5 12:44 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Icebrg	1/18/2008 5:11:15 PM
	of 2240

Biomarker could lead to new treatment for cancer and Crohn's disease 26 December 2007 Cambridge Enterprise Limited, the commercialisation office of the University of Cambridge, has completed a licence agreement with Medarex, Inc. for the potential development of a therapeutic drug to treat cancer and autoimmune diseases. A team from the University identified a cell surface marker that is expressed at high levels in certain cancer cells and in some tissues affected by autoimmune diseases (such as Crohn's disease) but at lower levels in tissues unaffected by disease. This marker could therefore potentially be used as a ‘target' for novel antibody based-medicines. The marker was identified by Professor John Trowsdale, Dr Rob Eagle and Dr Louise Bacon in the University of Cambridge, Department of Pathology. Professor Trowsdale commented: “Our initial studies on this protein have been fascinating and we are continuing our research on how it functions in health and disease. Meanwhile, we are delighted that Medarex plans to use its technology to generate antibodies to this target, which may lead to the development of novel therapeutics.” Dr Andrew Walsh, Technology Manager at Cambridge Enterprise said: “We are very pleased to have secured this agreement with Medarex. The company's track record in developing antibody based therapies makes them a very attractive licensee.” Medarex is a US based company specialising in the development of fully human antibody therapeutics. admin.cam.ac.uk

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next